Your browser doesn't support javascript.
loading
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Kamposioras, Konstantinos; Papaxoinis, George; Dawood, Mohamed; Appleyard, Jordan; Collinson, Fiona; Lamarca, Angela; Ahmad, Usman; Hubner, Richard A; Wright, Francesca; Pihlak, Rille; Damyanova, Iva; Razzaq, Bilal; Valle, Juan W; McNamara, Mairéad G; Anthoney, Alan.
Afiliação
  • Kamposioras K; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Papaxoinis G; Second Department of Oncology, Agios Savvas Anticancer Hospital, Athens, Greece.
  • Dawood M; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Appleyard J; Barts and The London School of Medicine and Dentistry, London, UK.
  • Collinson F; Department of Medical Oncology, Leeds Institute for Medical Research, St James' Institute of Oncology, St James' University Hospital, University of Leeds, Leeds, UK.
  • Lamarca A; Department of Medical Oncology, The Christie NHS Foundation Trust/Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Ahmad U; Department of Medical Oncology, The Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.
  • Hubner RA; Department of Medical Oncology, The Christie NHS Foundation Trust/Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Wright F; Department of Medical Oncology, Leeds Institute for Medical Research, St James' Institute of Oncology, St James' University Hospital, University of Leeds, Leeds, UK.
  • Pihlak R; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Damyanova I; Department of Medical Oncology, The Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.
  • Razzaq B; Department of Medical Oncology, The Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.
  • Valle JW; Division of Cancer Sciences, University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.
  • McNamara MG; Division of Cancer Sciences, University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.
  • Anthoney A; Department of Medical Oncology, Leeds Institute for Medical Research, St James' Institute of Oncology, St James' University Hospital, University of Leeds, Leeds, UK.
Acta Oncol ; 61(5): 583-590, 2022 May.
Article em En | MEDLINE | ID: mdl-35392758
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article